



CURRICULUM VITAE

Brian F. Chapin, MD

PRESENT TITLE AND AFFILIATION

Primary Appointment

Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Fellowship Program Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Director of Clinical Research, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1373
Houston, TX 77030
Phone: 713-792-3250
Fax: 713-792-3474

EDUCATION

Degree-Granting Education

Siena College, Loudonville, NY, BS, Summa Cum Laude, 2000, Biology

Georgetown University School of Medicine, Washington, DC, MD, 2004, Medicine

Postgraduate Training

Clinical Internship, General Surgery, Massachusetts General Hospital, Boston, MA, 2004-2005

Clinical Residency, General Surgery, Massachusetts General Hospital, Boston, MA, 2005-2006

Clinical Residency, Urology, Massachusetts General Hospital, Boston, MA, 2006-2009

Clinical Fellowship, Urologic Oncology, UT MD Anderson Cancer Center, Houston, TX, 2010-2012

CREDENTIALS

Board Certification

American Board of Urology, 2/2014-2/2024

Licensures

Active

Texas Medical Board, TX, N6214, 2/2012-2/2022

Drug Enforcement Administration Registration, TX, FC1707453, 7/2012-8/2021

Texas Department of Public Safety Registration, TX, 60174615, 1/2013-2/2022

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Assistant in Urology, Department of Urology, Massachusetts General Hospital, Boston, MA, 2009-2010

Clinical Specialist, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-2012

Assistant Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-2018

Co-Director of Clinical Research, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016-present

Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present

Administrative Appointments/Responsibilities

Administrative Chief Resident, Children's Hospital Boston, Boston, MA, 7/2008-9/2008

Administrative Chief Resident, Massachusetts General Hospital, Boston, MA, 12/2008-6/2009

Administrative Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2011-10/2011

Rotation Site Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2013-present

Fellowship Program Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2016-present

Other Appointments/Responsibilities

Member, Education Program Directors Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016-present

Member, Program Evaluation Committee, The University of Texas Health Science Center, Houston, TX, 2016-present

Faculty Appointment, MD Anderson Leadership Institute's Leading Others: Accelerate Program - Deep Dive into Competency Factors: Self-Management; People Leadership; Business Knowledge, Thinking and Service Orientation, Houston, TX, 4/2019-1/2020

Endowed Positions

N/A

Consultantships

Janssen Scientific Affairs, LLC, Phoenix, AZ, Consultant, 11/2018-present

Blue Earth Diagnostics, Dallas, Texas, Consultant, KOLMS Virtual Advisory Council, 8/2019-present

Military or Other Governmental Service

N/A

Institutional Committee Activities

Education Committee, Member, 2012-present

Surgical Education Committee, Member, 2013-present

Clinical Competency Committee, Member, 2013-present

General Medical Education Committee, Non-Voting Member, 3/2013-present

Residency Clinical Competency Committee, Member, 2014-present

Division of Surgery Task Force on Defining Educational Effort, Member, 1/2015-present

GME Program Directors Committee, Member, 2016-present

SWOG Genitourinary Committee, Awards Committee Chair, 4/2019-present

Operational Priority - Recruitment, Retention and Development Committee, Member, 4/2019-present

HONORS AND AWARDS

Summa Cum Laude, Siena College, Loudonville, New York, 2000

Cum Laude, Georgetown University School of Medicine, 2004

Harvard Medical School Resident Teaching Award, Massachusetts General Hospital, 2007

Partners in Excellence Award, Massachusetts General Hospital, 2007

American Urologic Association Foundation Research Scholarship, AUA, 2010-2011

Best of Posters AUA/JUA: Post-operative Complications from Cytoreductive Nephrectomy after Pre-surgical Targeted Therapy for Metastatic Renal Cell Carcinoma, AUA, 2011

Merit Award. Genitourinary Cancer Symposium (GU ASCO), American Society of Clinical Oncology, 2011

Distinguished Educator Award, UT MD Anderson Cancer Center, 2015

Teacher Of The Year, UT MD Anderson Cancer Center, 2016-2017

SUO 2019 Young Investigator Award, SUO Award Committee, 2019

RESEARCH

Grants and Contracts

Funded

Young Investigator, 20%, Impact of Local Therapy on Outcomes of Men with de novo Metastatic within Molecularly Defined Prostate Cancers, Prostate Cancer Foundation (PCF), PI - Ana Aparicio, 9/1/2017-8/31/2019, \$750,000 (\$375,000/year)

Co-Investigator, Pilot study investigating PSMA PET/MRI in detecting recurrent disease and aid in radiotherapy planning for patients with biochemically recurrent prostate cancer., 2020 ROSI Advanced Imaging Seed Awards, 7/1/2020-6/30/2021 (\$25,000/year)

Pending

N/A

Other

N/A

Completed

Principal Investigator, A Randomized, Phase II Trial of Best Systemic Therapy or Best Systemic Therapy Plus Definitive, Prostate Cancer Research Program (PCRP), 1/2013-1/2017, \$211,200 (\$105,600/year)

Principal Investigator, Does Radical Therapy Result in Substantial Long Term (>2 yrs) Sexual and Urinary Functional Decline Compared to Active Surveillance in Men Diagnosed with Prostate Cancer?, UTMDACC Cancer Survivorship Research Seed Money Grants, 5/2013-4/2015, \$50,000 (\$25,000/year)

Not Funded

N/A

Protocols

Funded

Collaborator, An International Phase 3 Randomized Trial of Autologous Dendritic Cell, Protocol 2012-0885, PI - Wood, Christopher, 2012-2016, \$1,821,973, Argos Therapeutics, Inc

Principal Investigator, A Phase II Randomized Trial of Best Systemic Therapy and Best Systemic Therapy with Definitive Treatment of the Primary in Metastatic Prostate Cancer, 2012-0705, 2013-2015, \$211,200, Prostate Cancer Research Program (PCRP)

Co-Principal Investigator, A Pilot Presurgical Study of Daratumumab (CD38 antagonist) in Men with High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy, 2017-0103, PI - Subudhi, Sumit, 2017-2020, \$299,213, MDACC, Institutional Moon Shot Fund, Janssen Pharmaceutical Companies of Johnson & Johnson

Collaborator, A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer, 2018-0265, PI - Efstathiou, Eleni, 2018-present, Alliance Foundation Trials, LLC

Co-Principal Investigator, A Single Arm Study of 6-months Neoadjuvant Apalutamide Prior to Radical Prostatectomy in Intermediate Risk Patients to Reduce the Frequency of Pathologic Features that Drive Post-Operative Radiation Therapy, 2015-0693, PI - Davis, John Warren, 2018-present, MDACC, Janssen Scientific Affairs, LLC

Principal Investigator, Randomized, Phase III Trial of Standard Systemic Therapy (SST) versus SST Plus Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer, S1802 RaPID, PI - Brian F. Chapin, 2018-present, NIH/SWOG

Principal Investigator, A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer, 2019-1036, 2019-present, Blue Earth Diagnostics

Collaborator, A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy, 2019-0601, PI - Efstathiou, Eleni, 2019-present, Janssen

Co-Principal Investigator, Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer, ECOG-ACRINEA8171, PI - Bathala, Tharakeswara, 2019-present, NCI

Co-Principal Investigator, A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy, 2020-0091, 2020-present, Blue Earth Diagnostics

Unfunded

Collaborator, Prospective Tissue Bank for Patients with or Suspected to Have Genitourinary Malignancies, LAB02-152, PI - Kim, Jeri, 2002

Collaborator, Expectant Management of Localized Renal Tumors: Natural History and Quality of Life, Protocol 2005-0426, PI - Matin, Surena, 2005, National Kidney Foundation

Collaborator, Positive Margin Characteristics after Radical Prostatectomy: A Comparison of Robotic, Laparoscopic, and Open Retropubic Radical Prostatectomy, DR07-0428, PI - Davis, John W, 2007

Collaborator, Robot-Assisted Radical Prostatectomy for High Risk Prostate Cancer, DR10-0554, PI - Davis, John W, 2010

Collaborator, Pre-surgical Androgen Deprivation Therapy with or without Axitinib in Previously Untreated Prostate Cancer Patients with Known or Suspected Lymph Node Metastasis, 2011-0231, 2011

Collaborator, Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging, 2012-0926, PI - Choi, Haesun, 2012

Collaborator, Development of New Human Prostate Cancer Biological Models, PA12-0482, PI - Araujo, John Charles, 2012

Collaborator, A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma, 2013-0444, 2013

Collaborator, A Pilot Study of Presurgical Tremilimumab With or Without Tissue Cryoablation in Patients with Metastatic Renal Cell Carcinoma, 2013-0539, 2013

Collaborator, Characterization of Circulating and Disseminated Tumor Cells, Bone Marrow-Derived Cells and Cytokines and Angiogenic Factors in Prostate Cancer: Correlation with Disease Progression and Response to Therapy, PA13-0247, 2013

Principal Investigator, Immunohistochemical Staining of Immune Cells in Radical Prostatectomy and Prostate Biopsy Specimens, PA13-0413, 2013

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

2014 Prostate Cancer Research Program (PCRP), DOD, Scientist Reviewer, 2014

Prostate Cancer Foundation Challenge Awards, PCF, Grant Reviewer, 2016

Netherlands Organization for Scientific Research, NIH, External Grant Reviewer, 2017

GU Steering Committee (GUSC)-NRG-GU1934, "Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-intensification and Intensification Clinical Trial Evaluation (GUIDANCE)", NIH, Grant Reviewer, 2020-present

International Committee for the Clinical Research in Cancer (CIR2C), French National Cancer institute (INCa), Expert, PROJECT PHRC-K20-096 BLANCHARD, 2020-present

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Oyelese Y, Tchabo JG, Chapin BF, Nair A, Hanson P, McLaren R. Conservative management of uterine rupture diagnosed prenatally on ultrasound. *Ultrasound in Medicine* 22:977-80, 2003. PMID: 14510271.
2. Eisner BH, Feldman AS, Chapin BF, Dretler SP. "Blind coning"--using the stone cone for removal of intramural ureteral calculi. *Urology* 69(4):773-75, 4/2007. PMID: 17445670.
3. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma venous tumor thrombus. *Eur Urol* 59(6):912-28, 6/2011. e-Pub 2/2011. PMID: 21367518.
4. Chapin BF, Delacroix SE, Wood CG. The role of lymph node dissection in renal cell carcinoma. *Int J Clin Oncol* 16(3):186-94, 6/2011. e-Pub 4/2011. PMID: 21523561.
5. Delacroix SE, Chapin BF, Chen JJ, Noguerras-Gonzalez GM, Tamboli P, Matin SF, Wood CG. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? *J Urol* 186(4):1236-41, 10/2011. e-Pub 8/2011. PMID: 21849197.
6. Chapin BF, Delacroix SE, Culp SH, Noguerras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of pre-surgical targeted therapy in the setting of metastatic renal cell carcinoma. *Eur Urol* 60(5):964-71, 11/2011. e-Pub 5/2011. PMID: PMC4378825.
7. Wirth GJ, Psutka SP, Chapin BF, Wu S, Wu CL, Dahl DM. Midterm Oncological Outcomes of Laparoscopic vs Open Radical Prostatectomy (RP). *BJU Int* 112(2):190-7, 7/2013. e-Pub 4/2013. PMID: 23601185.
8. Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaledone MC, Sooriakumaran P, Wiklund PN, Chapin BF. Treatment of the Primary Tumor

- in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. *Eur Urol*. e-Pub 5/2015. PMID: 26003223.
9. Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. *Urology* 86(1):10-5, 7/2015. e-Pub 6/2015. PMID: 26048432.
 10. Chapin BF. Optimal management of prostate cancer with lethal biology - state-of-the-art local therapy. *Asian J Androl* 17(6):888-91, Nov-Dec, 11/2015. e-Pub 6/2015. PMID: 26178396.
 11. Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. *Future Oncol* 12(5):687-99, 3/2016. e-Pub 2/2016. PMID: 26839141.
 12. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. *Clin Genitourin Cancer* 14(2):130-8, 4/2016. e-Pub 10/2015. PMID: 26558524.
 13. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. *BJU Int* 118(1):68-76, 7/2016. e-Pub 7/2015. PMID: PMC4808616.
 14. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. *J Clin Oncol* 34(24):2835-42, 8/2016. e-Pub 6/2016. PMID: 27325855.
 15. Blanchard P, Davis JW, Frank SJ, Jeri K, Pettaway CA, Pugh TJ, Pisters LL, Mahmood U, Ward JF, Choi S, Chapin BF, Hoffman KE, Navai N, McGuire SE, Matin SF, Nguyen QN, Thaker NG, Chen HC, Wang X, Kuban DA. How to Counsel Patients With Localized Prostate Cancer About Treatment Selection: Quality-of-Life Results of a Prospective Single-Institution Cohort. *Int J Radiat Oncol Biol Phys* 96(2S):E534-E535, 10/2016. PMID: 27674949.
 16. Williams SB, Chapin BF. Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom? *Eur Urol*. e-Pub 11/2016. PMID: 27815080.
 17. Bayne CE, Williams -B, Chapin BF. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. *Eur Urol* 2016;69:775-87. *Eur Urol* 71(2):e51, 2/2017. e-Pub 7/2016. PMID: 27461403.
 18. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. *Urol Oncol* 35(4):125-134, 4/2017. e-Pub 2/2017. PMID: 28190749.
 19. Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BF. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. *Cancer* 123(9):1617-1624, 5/2017. e-Pub 1/2017. PMID: 28099688.
 20. Metcalfe MJ, Chapin BF. Editorial Comment. *Urology*. e-Pub 5/2017. PMID: 28550942.
 21. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer. *BJU Int*. e-Pub 7/2017. PMID: 28710901.
 22. Williams SB, Huo J, Chapin BF, Smith BD, Hoffman KE. Impact of urologists' ownership of radiation equipment in the treatment of prostate cancer. *Prostate Cancer Prostatic Dis* 20(3):300-304, 9/2017. e-Pub 3/2017. PMID: 28349981.
 23. Reichard CA, Chapin BF. Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders? *Eur Urol* 72(3):352-353, 9/2017. e-Pub 5/2017. PMID: 28552614.
 24. Chapin BF, Bellmunt J. 'Working toward understanding oligo and polymetastatic prostate cancer'. *Curr Opin Urol* 27(6):532, 11/2017. PMID: 28922341.

25. Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW, Troncoso P. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. *Prostate Cancer Prostatic Dis.* e-Pub 12/2017. PMID: 29230008.
26. Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW. A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. *Urol Oncol* 36(1):13.e19-13.e25, 1/2018. e-Pub 9/2017. PMID: 28964658.
27. Reichard C, Chapin BF. Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy. *Eur Urol Focus.* e-Pub 2/2018. PMID: 29439879.
28. Altok M, Bahaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW. Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection. *BJU Int.* e-Pub 2/2018. PMID: 29446205.
29. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life following brachytherapy or bilateral nerve sparing robotic prostatectomy for prostate cancer: a prospective cohort. *BJU Int* 121(4):540-548, 4/2018. e-Pub 10/2017. PMID: 28941030.
30. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. *Prostate Cancer Prostatic Dis* 21(1):4-21, 4/2018. e-Pub 12/2017. PMID: 29230009.
31. Cartapatti M, Machado RD, Muller RL, Magnabosco WJ, Santos AC, Chapin BF, Melani A, Talvane A, Tobias-Machado M, Faria EF. Synchronous abdominal tumors: is combined laparoscopic surgery in a single approach a safe option? *Int Braz J Urol* 44(3):483-490, May-Jun, 5/2018. PMID: PMC5996783.
32. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. *Prostate Cancer Prostatic Dis.* e-Pub 7/2018. PMID: 29988098.
33. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical prostatectomy in metastatic castration-resistant prostate cancer: feasibility, safety, and quality of life outcomes. *Eur Urol* 74(2):140-143, 8/2018. e-Pub 4/2018. PMID: 29656854.
34. Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis J. Coffee, Caffeine Metabolism Genotype, and Disease Progression in Localized Prostate Cancer Patients Managed with Active Surveillance. *J Urol.* e-Pub 9/2018. PMID: 30179617.
35. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. *Int J Urol.* e-Pub 9/2018. PMID: 30253446.
36. Chapin BF. Clinical Trials in Urology. *Urol Oncol* 37(5):303-304, 5/2019. e-Pub 3/2019. PMID: 30904395.
37. Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. *Eur Urol Oncol* 2(3):257-264, 5/2019. e-Pub 1/2019. PMID: 31200839.
38. Kukreja JB, Thompson IM, Chapin BF. Organizing a clinical trial for the new investigator. *Urol Oncol* 37(5):336-339, 5/2019. e-Pub 2/2018. PMID: 29395953.
39. Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. *Eur Urol Focus.* e-Pub 5/2019. PMID: 31076357.

40. Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW, Chapin BF. Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome? *BJU Int* 124(2):282-289, 8/2019. e-Pub 2/2019. PMID: 30653804.
41. Reichard CA, Chapin BF. Editorial Comment. *Urology* 131:174, 9/2019. PMID: 31451157.
42. Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF. Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment. *BJU Int* 124(5):811-819, 11/2019. e-Pub 5/2019. PMID: 31009137.
43. Ranasinghe WKB, Reichard CA, Chapin BF. Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care. *Eur Urol* 76(5):543-545, 11/2019. e-Pub 6/2019. PMID: PMC6922301.
44. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. *Cancer* 126(3):506-514, 2/2020. e-Pub 11/2019. PMID: PMC6980273.
45. Baack Kukreja J, Bathala TK, Reichard CA, Troncso P, Delacroix S, Davies B, Eggner S, Saldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. *Prostate Cancer Prostatic Dis* 23(1):172-178, 3/2020. e-Pub 9/2019. PMID: PMC7027969.
46. Ranasinghe WKB, Reichard CA, Bathala T, Chapin BF. Management of cT4 Prostate Cancer. *Eur Urol Focus* 6(2):221-226, 3/2020. e-Pub 6/2019. PMID: 31266732.
47. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncso P, Madsen LT, Logothetis C, Kim J. Determining Clinically-Based Factors Associated with Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. *Urology* 138:91-97, 4/2020. e-Pub 12/2019. PMID: PMC7141963.
48. Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BF. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. *J Urol*:101097JU0000000000001074. e-Pub 4/2020. PMID: 32259468.
49. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. *Sci Transl Med* 12(537), 4/2020. PMID: 32238575.
50. Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. *BJU Int*. e-Pub 5/2020. PMID: 32357283.
51. Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu Y. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. *Clin Nucl Med* 45(5):349-355, 5/2020. PMID: 31977495.
52. Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. *BJU Int* 125(6):792-800, 6/2020. e-Pub 4/2020. PMID: 32176456.
53. Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. *Pract Radiat Oncol* 10(4):282-292, Jul - Aug, 7/2020. e-Pub 4/2020. PMID: PMC7395481.

54. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased frequency of Mesorectal and Perirectal LN involvement in T4 Prostate Cancers. *Int J Radiat Oncol Biol Phys* 107(5):982-985, 8/2020. e-Pub 4/2020. PMID: 32353391.
55. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. *Cancer* 126(16):3667-3673, 8/2020. e-Pub 5/2020. PMID: 32453443.

Invited Articles

1. Chapin BF, Delacroix SE, Wood CG. Renal cell carcinoma; what the surgeon and treating physician need to know. *AJR Am J Roentgenol* 196(6):1255-62, 6/2011. PMID: 21606286.
2. Chapin BF, Delacroix SE, Wood CG. The role of lymphadenectomy in renal cell carcinoma. *International Journal of Clinical Oncology* 16(3):186-94, 6/2011. PMID: 21523561.
3. Delacroix SE, Chapin BF, Wood CG. The role of lymph node dissection in renal cell carcinoma. *Urol Clin North Am* 38(4):419-28, vi, 11/2011. PMID: 22045173.
4. Chapin B, McGuire S, Aparicio A. Local Therapy in Metastatic Prostate Cancer: Does an Integrated Approach Improve Clinical Outcomes? 2015 Genitourinary Cancers Symposium Daily News, <http://gucasym.org/local-therapy-metastatic-prostate-cancer-does-integrated-approach-improve-clinical-outcomes>, 2/2015.
5. Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? *AJR Am J Roentgenol* 214(6):1248-1258, 6/2020. e-Pub 3/2020. PMID: 32130049.

Editorials

1. Chapin BF, Wood CG. The R.E.N.A.L. nephrometry nomogram: statistically significant, but is it clinically relevant? *Eur Urol* 60(2):249-51, 8/2011. e-Pub 4/2011. PMID: 21514040.
2. Chapin BF, McGuire SE, Aparicio A. Is Treatment of the Primary Tumor in Metastatic Prostate Cancer Justified? *Eur Urol* 65(6):1067-8, 6/2014. e-Pub 12/2013. PMID: 24411278.
3. Khaled D, Chapin BF. Determining the Key to Success for Radical Prostatectomy: Is There a Surrogate Measure for a Meaningful Clinical Outcome? RE: Groeben et al. *World J Urol*. e-Pub 12/2016.

Other Articles

1. Nyame YA, Tosoian JJ, Sundi D, Chapin BF, Klein EA, Ross A. Biochemical Failure among African American Men with High Risk Prostate Cancer. *AUA News* 23(2):1 and 5, 2/2018.
2. Reichard CA, Chapin BF. Local Therapy for de novo Metastatic Prostate Cancer - Who, Why, When? *AUA News* 24(1):1-3, 1/2019.

Abstracts

1. Chapin BF, Eisner B, Lahey S, Tabatabaei S. KTP laser photovaporization of prostate in patients with large volume prostates. New England Section of the American Urologic Association, 2007.
2. Eswara JR, Eisner BH, Chapin BF, McDougal WS. Long-term changes in renal function after radical and partial nephrectomy. 102nd Annual Meeting. American Urologic Association, 2007.
3. Chapin BF, Eisner BH, Samir AM, Eswara JR, Hunter SE, Maher MM, Hahn PF, Gervais DA, McGovern FJ, McDougal WS, Mueller PR. Natural history of renal oncocytoma diagnosed by percutaneous biopsy. New England Section of the American Urologic Association, 2008.
4. Chapin BF, Feldman AS, Dahl DM. Hydrodissection of the neurovascular bundles in laparoscopic radical prostatectomy: Impact on positive surgical margins. American Urological Association's National Meeting, 2009.
5. Chapin BF, Feldman AS, Psutka SP, Dahl DM. Predictors of post-prostatectomy incontinence: A multivariate analysis. New England Section of the American Urologic Association Annual Meeting, 2009.
6. Delacroix SE, Chapin BF, Cost N, Karam JA, Culp S, Abel EJ, Gonzalez G, Margulis V, Wood CG. Can contemporary targeted therapies provide clinically meaningful changes in renal cell carcinoma venous tumor thrombi? Genitourinary Cancers Symposium (GU ASCO) and American Urologic Association, 2011.

7. Delacroix SE, Chapin BF, Cost N, Karam JA, Culp S, Abel EJ, Gonzalez G, Margulis V, Wood CG. Can contemporary targeted therapies provide clinically meaningful changes in renal cell carcinoma venous tumor thrombi? Southeastern Sectional of the American Urologic Association, 2011.
8. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma. Southeastern Sectional of the American Urologic Association, 2011.
9. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after pre-surgical targeted therapy for metastatic renal cell carcinoma. American Urologic Association Annual Meeting, 2011.
10. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after pre-surgical targeted therapy for metastatic renal cell carcinoma. Genitourinary Cancer Symposium (GU ASCO), 2011.
11. Cost NG, Delacroix SE, Smith P, Youssef RF, Chapin BF, Karam J, Culp SH, Abel EJ, Rak GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma venous tumor thrombus. Society of Urologic Oncology. 2010, American Urologic Association, Orlando, Florida. 2011, ASCO 2011, J Clin Oncol 29: (suppl; abstr e15002), 2011.
12. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Timing of cytoreductive nephrectomy does not influence survival in metastatic renal cell carcinoma. American Urologic Association Annual Meeting, 2011.
13. Chapin, BF, Delacroix SE, et al. Can a Lymph node dissection alter outcomes in metastatic renal cell carcinoma? American Urological Association Annual Meeting, 2012.
14. Troncoso P, Nguyen JN, Prokhorova IN, Wang X, Li Ning Tapia EM, Achim MF, Davis JW, Chapin BF. Pathologic Features in Radical Prostatectomy Specimens Associated with Biochemical Failure in Patients with pT2 Prostate Cancer and Positive Surgical Margin. United States & Canadian Academy of Pathology, 3/2014.
15. Davis JW, Achim MF, Ward JF, Pettaway CA, Chapin BF, Wang X, Kuban DA, Frank SJ, Lee A, Pisters LL, Matin SF, Shah JB, Karam JA, Papadopoulos JN, Hoffman KE, Pugh TJ, Choi S, Logothetis C, Troncoso P, Kim J. Active Surveillance in Phenotypically Heterogeneous Early-Stage Prostate Cancer. J Clin Oncol 32(5s):5083, 5/2014.
16. Nguyen JN, Chapin BF, Prokhorova IN, Achim M, Wang X, Davis JW, Troncoso P. Positive Margin Length and Gleason Grade of Tumor Focus at the Margin Predict for Biochemical Failure After Radical Prostatectomy in Patients with pT2 Prostate Cancer. American Urological Association Annual Meeting, 5/2014.
17. Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, Ott L, Logothetis C, Aparicio A. A Prospective, Multicenter, Randomized Phase II Trial of Best Systemic Therapy (BST) or BST Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer. 2015 ASCO Annual Meeting, 5/2015.
18. Williams SB, Davis JW, Achim MF, Zurita AJ, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Effect of Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy in High-Risk Prostate Cancer on Surgical Morbidity: Contemporary Results Utilizing the Clavien System. J Clin Oncol 33(7s):66, 2015.
19. Mount A, William SB, Dinney C, Grossman HB, Pettaway CA, Chapin BF, Navai N, Matin SF, Graber WF, Kamat AM. Blue-light Cystoscopy's Effects on Management of Bladder Cancer When Compared to Traditional White-Light Cystoscopy. J Clin Oncol 34(Suppl 2S), 1/2016.
20. Tosoian JJ, Sundi D, Chapin BF, Antonarakia ES, Chappidi M, Alam R, Glavaris S, Karnes RJ, Pienta KJ, Tran PT, Schaeffer EM, Ross A. Contemporary Treatment Patterns and Short-Term Outcomes in Men with very High-Risk Prostate Cancer. J Clin Oncol 34(Suppl 2S), 1/2016.
21. Mount A, William SB, Dinney C, Grossman HB, Pettaway CA, Chapin BF, Navai N, Matin SF, Graber WF, Kamat AM. Examining the Effect that Prior Bladder Manipulation and BCG Treatment Have on False Positive Rates of Blue-Light Cystoscopy Biopsies. J Clin Oncol 34(Suppl 2S), 1/2016.

22. Achim M, Matin S, Chapin B, Troncoso P, Tapia ELN, Guerrero M, Prokhorova I, Olson A, Haddad Z, Lam L, Yousefi K, Buerki C, Davicioni E, Davis JW. Assessing Decipher for Predicting Lymph Node Positive Disease Among Men Diagnosed with Intermediate Risk Disease Treated with Prostatectomy and EPLND. 17th Annual Meeting of the Society of Urologic Oncology, 12/2016.
23. Ghaffary C, Duan Z, Chapin B, Dafashy T, Kosarek C, Chamie K, Kim S, Hoffman K, Giorando S, Williams S. Impact of Proximity to NCI- and NCCN-Designated Cancer Centers on Outcomes for Patients with Prostate Cancer Undergoing Radical Prostatectomy Using Big Data: A Seer-Medicare Analysis. 17th Annual Meeting of the Society of Urologic Oncology, 12/2016.
24. Williams S, Kosarek C, Huo J, Chamie K, Smaldone M, Fang J, Ynalvez L, Kim S, Hoffman K, Giordano S, Chapin B. Overall Survival Advantage with Radical Prostatectomy for Prostate Cancer. 17th Annual Meeting of the Society of Urologic Oncology, 12/2016.
25. Alam R, Tosoian JJ, Nyame YA, Wilkins L, Yousefi K, Chappidi MR, Reddy CA, Humphreys EB, Sundi D, Chapin BF, Stephenson AJ, Klein EA, Ross AE. A Novel Nomogram to Predict Postoperative Biochemical Recurrence in Patients with Localized High-Risk Prostate Cancer. *J Urol* 197(4):Supplement, e130–e131, 4/2017.
26. Achim M, Matin S, Chapin B, Troncoso P, Tapia ELN, Guerrero M, Prokhorova I, Olson A, Haddad Z, Margrave J, Chelliserry J, Lam L, Yousefi K, Buerki C, Davicioni E, Davis J. Assessing Decipher for predicting lymph node positive disease among men diagnosed with intermediate risk disease treated with prostatectomy and ePLND. 197(4):Supplement, e848–e849, 4/2017.
27. Altok M, Ward J, Chapin B, Pisters L, Pettaway C, Davis J. Cost Analysis of Different Prostate Biopsy Modalities. *J Urol* 197(4):Supplement, e821, 4/2017.
28. Ghaffary C, Duan Z, Chapin B, Dafashy T, Kosareck C, Chamie K, Kim S, Ahlering T, Davis J, Giordano S, Williams S. IMPACT OF PROXIMITY TO NCI- AND NCCN-DESIGNATED CANCER CENTERS ON OUTCOMES FOR PATIENTS WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY. *J Urol* 197(4):Supplement, e632–e633, 4/2017.
29. Nyame Y, Tosoian J, Wilkins L, Alam R, Yousefi K, Chappidi M, Reddy C, Humphreys E, Sundi D, Chapin B, Stephenson AJ, Klein E, Ross A. Increased Risk of Biochemical Failure After Radical Prostatectomy Among African American Men with High Risk Prostate Cancer. 197(4):Supplement, e168, 4/2017.
30. Sundi D, Tosoian J, Nyame Y, Achim M, Alam R, Reddy C, Wilkins L, Narang A, Stephenson A, Davis J, Schaeffer E, Ross A, Klein E, Chapin B. Outcomes of Very-High-Risk Prostate Cancer: Validation Study from 3 Institutions over 10 years. 197(4), 4/2017.
31. Wilkins L, Ridwan A, Tosoian JJ, Nyame YA, Yousefi K, Chappidi MR, Reddy CA, Humphreys EB, Sundi D, Chapin BF, Stephenson AJ, Klein EA, Ross AE. Predicting Metastasis in Men with Localized High Risk Prostate Cancer Undergoing Radical Prostatectomy. *J Urol* 197(4):Supplement, e169–e170, 4/2017.
32. Reichard C, Nyame Y, Sundi D, Tosoian J, Wilkins L, Alam R, Stephenson A, Klein E, Ross A, Davis J and Chapin BF. Does Time From Diagnosis To Treatment Of Very High Or High Risk Prostate cancer Affect Outcome? 18th Annual Meeting of the Society of Urologic Oncology (SUO), 11/2017.
33. Truong M., Kukreja, J., Rais-Bahrami, S., Barashin N., Wang B., Nuffer Z., Hae Park J., Lam K., Frye T., Nix J., Thomas J., Feng C., Chapin B., Davis J., Hollenberg G., Oto A., Eggener S., Joseph J., Weinberg E., and Messing E. Multi-Institutional Development Of A Pretest Probability Calculator For High Risk Lesions On Multiparametric Prostate MRI. 18th Annual Meeting of the Society of Urologic Oncology (SUO), 11/2017.
34. Reichard C., Bathala T., Gregg J., Kukreja J., Achim M., Davis J. and Chapin B. CT Scan Has High Rate Of Incidental Findings And Low Clinical Utility In A Cohort Of High Risk Prostate Cancer Patients Stages With 99mTc Bone Scan And Pelvic MR. 18th Annual Meeting of the Society of Urologic Oncology (SUO), 12/2017.
35. Ghaffary C, Dafashy T, Kosarek CD, Duan Z, Chapin BF, Chamie K, Kim SP, Fang JE, Kerr P, Hoffman KE, Giordano SH, Orihuela E, Williams SB. Impact of Proximity to NCI- and

- NCCN-designated Cancer Centers on Outcomes for Patients with Prostate Cancer Undergoing Radical Prostatectomy. *J Clin Oncol* 35(Suppl 6S):Abstract 14, 2017.
36. Kosarek CD, Williams SB, Huo J, Chamie K, Smaldone MC, Fang JE, Ghaffary C, Kerr P, Ynalvez L, Kim SP, Giordano SH, Chapin BF. Overall Survival Advantage with Radical Prostatectomy for Prostate Cancer. *J Clin Oncol* 35(Suppl 6S):Abstract 37, 2017.
 37. Nyame YA, Tosoian JJ, Alam R, Wilkins L, Yousefi K, Chappidi M, Reddy CA, Humphreys EB, Sundi D, Chapin BF, Stephenson AJ, Klein EA, Ross A. Predicting Disease Progression in Men with Localized High Risk Prostate Cancer Undergoing Radical Prostatectomy. *J Clin Oncol* 35(Suppl 6S):Abstract 51, 2017.
 38. Gregg J, Reichard CA, Wang X, Chapin BF, Pister LL, Pettaway CA, Ward JF, Achim MF, Choi S, Kuban DA, Davis JW, Kim J. Improving risk-stratification of localized prostate cancer in a prospective active surveillance cohort. 2018 Genitourinary Cancers Symposium, 2/2018.
 39. Reichard CA, Gregg J, Bathala T, Achim MF, Davis JW, Chapin BF. Is expanded radiographic criteria for clinically positive lymph nodes associated with outcome in pathologically node positive prostate cancer? 2018 Genitourinary Cancers Symposium, 2/2018.
 40. Reichard CA, Gregg J, Achim MF, Aparicio A, Pister LL, Ward JF, Davis JW, Chapin BF. Radical prostatectomy in metastatic castration-resistant prostate cancer: Feasibility, safety, and quality of life outcomes. 2018 Genitourinary Cancers Symposium, 2/2018.
 41. Oke O, Tang C, Shaaban S, Xiao L, Reichard CA, Chapin BF, Anscher MS, Aparicio A. Impact of definitive local therapy (LT) in men with primary small cell (or poorly differentiated neuroendocrine) prostate carcinomas (pSCPC). 2018 ASCO Annual Meeting, 6/2018.
 42. Reichard C, Duplisea J, Nyame Y, Sundi D, Tosoian J, Achim M, Wilkins L, Alam R, Stephenson A, Klein E, Ross A, Allaf M, Davis J, Chapin B. Clinically Significant Gleason 8 Downgrading in Sub-Stratified High Risk Prostate Cancer Occurs Infrequently. 19th Annual Meeting of the Society of Urologic Oncology (SUO), 11/2018.
 43. Gregg JR, Zheng J, Lopez D, Reichard C, Chapin B, Kim J, Davis J, Daniel C. Diet Quality and Disease progression Among Localized Prostate Cancer Patients on Active Surveillance. 19th Annual Meeting of the Society of Urologic Oncology (SUO), 11/2018.
 44. Altok M, Chapin B, Matin S, Achim M, Davis J. Omitting A Lymph Node Dissection At Radical Prostatectomy: Are There Consequences For Unexpected Upgrading/Upstaging? AUA 2019, 5/2019.
 45. Ajay D, Li H, Barrett-Harlow B, Nguyen J, Benson C, Wang X, Chapin B, Davis J, Westney OL. Perioperative Factors Contributing The Delayed Return To Continence After Radical Prostatectomy. AUA 2019, 5/2019.
 46. Aparicio A, Zhang M, Ramesh N, Wang X, Corn PG, Zurita AJ, Davis JW, Pettaway CA, Adibi M, McGuire SE, Tu SM, Wang J, Subudhi SK, Elsheshtawai M, Efstathiou E, Logothetis C, Navin N, Troncoso P, Chapin BF. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). 2019 ASCO Annual Meeting, 6/2019.
 47. Chapin BF, Wang X, Zhang M, Corn PG, Zurita AJ, Elsheshtawi M, Davis JW, Pettaway CA, Adibi M, Gleave M, Cooperberg MR, Smaldone MC, McGuire SE, Tu SM, Wang J, Subudhi SK, Efstathiou E, Logothetis C, Troncoso P, Aparicio A. Local Therapy for de novo Metastatic Prostate Cancer - Who, Why, When? 2019 ASCO Annual Meeting, 6/2019.
 48. Amado JZ, Tidwell RS, Troncoso P, Chapin BF, Harris D, Pister LL, Araujo JC, Pettaway CA, Aparicio A, Tu SM, Papadopoulos JN, Wang J, Logothetis C, Pagliaro LC, Davis JW. Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis. 2019 ASCO Annual Meeting, 6/2019.
 49. Ranasinghe W, Brooks N, Elsheshtawi M, Davis J, Bathala T, Troncoso P, Aparicio A, Tu SM, Chapin BF. Patterns of Metastases of Prostatic Ductal Adenocarcinoma. 20th Annual Meeting of the Society of Urologic Oncology (SUO), 12/2019.

Book Chapters

1. Chapin BF, Delacroix SE, Wood CG. Cytoreductive Nephrectomy for Advanced Disease in Renal Cell Cancer: Principles and Practice. In: *Kidney Cancer*. Ed(s) Lara P, Jonasch E. Springer, 2012.
2. Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban D, Efstathiou E, Aparicio A. Neoplasms of the Prostate. In: *Holland-Frei Cancer Medicine*, 9th, 2017. PMID: 978-1-118-93469-2.
3. Chapin BF. Positive Surgical Margins: How to Self-Evaluate and Improve. In: *Robot-Assisted Radical Prostatectomy: Beyond the Learning Curve*. Ed(s) Davis JW. Springer. In Press.

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

1. Chapin, BF. AUA Advanced Prostate Cancer Guidelines, 2019.

Other Publications

1. Commentary.

Chapin B. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. PracticeUpdate website. Available at: <http://www.practiceupdate.com/content/survival-improves-in-newly-diagnosed-metastatic-prostate-cancer-with-prostate-radiation-added-to-adt/40914/65/11/1>. Accessed August 08, 2016

2. Commentary.

Chapin B. Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients With Low-Volume Bone Metastasis? Results From a Prospective Case-Control Study. PracticeUpdate website. Available at: <http://www.practiceupdate.com/content/does-cytoreductive-prostatectomy-really-have-an-impact-on-prognosis-in-prostate-cancer-patients-with-low-volume-bone-metastasis/58666/65/3/1>. Accessed June 05, 2018

3. Roundtable Discussion. A Roundtable discussion with Brian F. Chapin, MD; Jonathan I. Epstein, MD; and Maha Hussain, FACP, FASCO - When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance? The ASCO Post website. Available at:

<http://www.ascopost.com/issues/july-25-2018/when-can-patients-with-gleason-6-prostate-cancer-safely-undergo-active-surveillance/>. Accessed July 25, 2018

4. Commentary.

Chapin BF. Elsevier PracticeUpdate - <https://www.practiceupdate.com/content/implementation-of-germline-testing-for-prostate-cancer/102035/65/3/1>. **Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.**

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Oncology Senior Editor, AUA CORE Curriculum - Oncology, Urinary Diversion and Adrenal, 2018-2021

Oncology Senior Consultant, AUA CORE Curriculum - Oncology, Urinary Diversion and Adrenal, 2019-2022

Member of Editorial Review Board

N/A

Journal Reviewer

Journal Reviewer, American Journal of Roentgenology, 2010-present

Journal Reviewer, European Urology, 2011-present

Journal Reviewer, Surgical Innovation, 2011-present

Journal Reviewer, Journal of Urology, 2012-present

Journal Reviewer, Urologic Oncology, 2012-present

Journal Reviewer, British Journal of Urology International, 2013-present

Journal Reviewer, Clinical Genitourinary Cancer, 2014-present

Journal Reviewer, The Prostate, 2014-present

Journal Reviewer, European Urology Focus, 2017-present

Journal Reviewer, Journal of Clinical Oncology, 2017-present

Journal Reviewer, European Urology Oncology, 2018-present

Other Editorial and Review Activities

Guest Editorship, Current Opinions in Urology, Clinical Trials in Urology, 2017

Guest Editorship, Current Opinions in Urology, Cancer Genetics in Urologic Practice, 2019

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

Instructor, Troubleshooting and Device Failure, 6th Annual Minimally Invasive New Technology in Oncologic Surgery (MINTOS), UT MD Anderson Cancer Center
9/2012

Instructor, Minimally Invasive New Technology in Oncologic Surgery (MINTOS) Cadaver Course, UT MD Anderson Cancer Center/Baylor College of Medicine MECCA Lab
5/2014

Instructor, Minimally Invasive New Technology in Oncologic Surgery (MINTOS) Cadaver Course
4/2015

Instructor, Minimally Invasive New Technology in Oncologic Surgery (MINTOS) Cadaver Course
4/2016

Instructor, Minimally Invasive New Technology in Oncologic Surgery (MINTOS) Cadaver Course

9/2017

Other Formal Teaching

Chair, SUO Friday Lecture Series
4/2020-6/2020

Chair, Division of Surgery August Trainee Education Series - Burnout and Resilience
August Series, 8/2020

Chair, Division of Surgery August Trainee Education Series - Financial Planning
August Series, 8/2020

Chair, Division of Surgery August Trainee Education Series - Research Resources
August Series, 8/2020

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

Surgical instruction and education for The University of Texas at Houston and
University of Texas Medical Branch Residents

Surgical instruction and education for The University of Texas MD Anderson Cancer
Center Urologic Oncology Fellows

Other Supervisory Teaching

N/A

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Faculty Member, 2017 Castration-Resistant Prostate Cancer (CRPC) Live Forum for
Urology Residents & Fellows: Initial Management of Advanced Prostate Cancer and
Characterization of Castrate-Resistant Disease, American Urological Association (AUA) in
partnership with the Society for Urologic Oncology (SUO)
9/2017

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

8th Urologic Oncology: Advances in Clinical Practice, Houston, TX, Member, Planning Committee, 11/2013

9th Urologic Oncology: Advances in Clinical Practice, Houston, TX, Member, Planning Committee, 11/2014

10th Urologic Oncology: Advances in Clinical Practice, Houston, TX, Co- Chair, 11/2015

SWOG Cytoreduction Symposium: The Role of Cytoreductive Surgery in Metastatic Genitourinary Cancers, Chicago, IL, Chair, 9/2016

11th Urologic Oncology: Advances in Clinical Practice, Houston, TX, Chair, 10/2016

12th Urologic Oncology: Advances in Clinical Practice, Houston, TX, Co-Chair, 10/2017

13th Urologic Oncology: Advances in Clinical Practice, Houston, TX, Co-Chair, 11/2018

Presentations at National or International Conferences

Invited

Chapin BF, Feldman AS, Psutka SP, Dahl DM. Predictors of post-prostatectomy incontinence: A multivariate analysis, New England Section of the American Urologic Association Annual Meeting, 2009

Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma, Southeastern Sectional of the American Urologic Association, 2011

Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Post operative complications from cytoreductive nephrectomy after pre-surgical targeted therapy for metastatic renal cell carcinoma, Genitourinary Cancer Symposium (GU ASCO), Orlando, FL, 2/2011

Can a lymph node dissection alter outcomes in metastatic renal cell carcinoma?, Podium Session, American Urologic Association Annual Meeting, Atlanta, GA, 5/2012

Con: What is the Role of Lymph Node Dissection in Locally Advanced RCC?, 2013 International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 12/2013

Control of the primary tumor in patients with metastatic prostate cancer: Is it important?, 2013 International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 12/2013

Pro: PSA Screening and Early Detection Have Improved Outcomes in Prostate Cancer, 2013 International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 12/2013

Prostate Cancer Session Moderator, 2013 International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 12/2013

What is the best therapy for clinically localized prostate cancer?, 2013 International Uro-Oncological Symposium: Update on the Management of Urologica Malignancies, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 12/2013

Live Surgery Moderator: Robotic assisted Radical Prostatectomy-Favorable Risk, Eurasian Uro-Oncology Society Training Meetings 1, Houston, TX, 1/2014

Pelvic Lymph Node Dissection: Update on Technique, Patient Selection, Outcomes, Eurasian Uro-Oncology Society Training Meetings 1, Houston, TX, 1/2014

Prostate Cancer Scientific Chair, Eurasian Uro-Oncology Society Training Meetings 1, Houston, TX, 1/2014

The Role of Local Therapy in N1 or M1 Disease, Eurasian Uro-Oncology Society Training Meetings 1, Houston, TX, 1/2014

Evidence Based Case Scenarios Where Surgery is Best, American Urological Association, Orlando, FL, 5/2014

Robotic Surgery: Do Outcomes Support Increased Cost?, Oncology Nursing Society, Chicago, IL, 5/2014

Moderator: The Challenge of Locally Advanced, Aggressive Disease, UT MD Anderson Cancer Center and MD Anderson Physicians Network Symposium, Boston, MA, 7/2014

Why Should a Patient Choose Active Surveillance?, MD Anderson Cancer Center and MD Anderson Physicians Network Symposium, Boston, MA, 7/2014

The Role of Local Therapy, 2015 Genitourinary Cancers Symposium (GU ASCO), Orlando, FL, 2/2015

Best of GU ASCO - Localized prostate cancer, II International Symposium on Multidisciplinary Treatment of Uro-Oncology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 3/2015

Prostate cancer: Key messages cases discussion I, II International Symposium on Multidisciplinary Treatment of Uro-Oncology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 3/2015

Prostate cancer: Key messages cases discussion II, II International Symposium on Multidisciplinary Treatment of Uro-Oncology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 3/2015

Testicular cancer: Key messages cases discussion -Urology, II International Symposium on Multidisciplinary Treatment of Uro-Oncology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 3/2015

Urothelial cancer: Key messages cases discussion II, II International Symposium on Multidisciplinary Treatment of Uro-Oncology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 3/2015

Control of the Primary Tumor in the Setting of Advanced Prostate Cancer, 2015 AUA Annual Meeting, Arab Association of Urology (AAU), New Orleans, LA, 5/2015

Panel Discussion/Debate: Dilemmas in Prostate Cancer Screening Diagnosis & Management, 2015 AUA Annual Meeting, Arab Association of Urology, New Orleans, LA, 5/2015

How and When to do an Extended Lymph Node Dissection at Radical Prostatectomy, 2015 International Uro-Oncological Symposium, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 11/2015

Local Therapy in Metastatic Prostate Cancer: What Have We Learned and Where are We Headed?, 2015 International Uro-Oncological Symposium, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 11/2015

Robotic Live Demonstration: Radical Prostatectomy, 2015 International Uro-Oncological Symposium, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 11/2015

What is the Best Treatment for High Risk Prostate Cancer, 2015 International Uro-Oncological Symposium, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, 11/2015

State of the Art Lecture IV: Local Control for Metastatic Prostate Cancer, New England Section American Urological Association, Portland, ME, 9/2016

Role of Definitive Therapy in Oligometastatic Disease, Society of Urologic Oncology, San Antonio, TX, 12/2016

Prostate Cancer: Advanced (Including Drug Therapy) II (Session Moderator), American Urological Association, Boston, MA, 5/2017

Chapin, BF. Clinical Urology Advanced Prostate Cancer: Management of Lymph Node Positive Prostate Cancer, 18th Asia-Pacific Prostate Cancer Conference 2017, Melbourne, Australia, 9/1/2017

Chapin, BF. 7th Da Vinci Prostatectomy Masterclass: High Risk and Metastatic Disease, 18th Asia-Pacific Prostate Cancer Conference 2017, Melbourne, Australia, 9/2/2017

Chapin, BF. 7th Da Vinci Prostatectomy Masterclass: Nerve Sparing: How I do It, 18th Asia-Pacific Prostate Cancer Conference 2017, Melbourne, Australia, 9/2/2017

Chapin BF. 7th Da Vinci Prostatectomy Masterclass: Unedited Case-Radical Prostatectomy-High Risk Disease, 18 Asia-Pacific Prostate Cancer Conference 2017, Melbourne, Australia, 9/2/2017

Locally-Advanced High-Risk Prostate Cancer Panel Discussion, Panelist, 96th Annual Meeting of the South Central Section of the AUA, Naples, FL, 11/2017

Prostate Cancer, Podium Session - Moderator, 96th Annual Meeting of the South Central Section of the AUA, Naples, FL, 11/2017

Chapin BF. Treatment of High Risk Advanced and M1 Disease: Is There a Role for Treatment of the Primary? - PRO, Speaker, SUO 2018 AUA/Spring Meeting, San Francisco, CA, 5/19/2018

Challenges in the management of high-risk and locally advanced disease, Chair, Global Congress on Prostate Cancer 2018 - PROSCA, Frankfurt, Germany, 6/28/2018

Current Controversies in (Oligo)Metastatic Disease - Treating the Primary, Speaker, Global Congress on Prostate Cancer 2018 - PROSCA, Frankfurt, Germany, 6/28/2018

Interactive round table discussions on real life cases, Chair, Global Congress on Prostate Cancer 2018 - PROSCA, Frankfurt, Germany, 6/30/2018

Local Treatment in Metastatic Prostate Cancer, 19th Asia-Pacific Prostate Cancer Conference, Brisbane, Australia, 8/24/2018

MDT Panel Case Discussion, Panelist, Brisbane, Australia, 8/24/2018

Techniques for Resection of High Risk Disease, 19th Asia-Pacific Prostate Cancer Conference, Brisbane, Australia, 8/24/2018

Focal Therapy for Prostate Cancer: A Minimalist Approach to a Giant Disease, Speaker, St. Luke's Medical Center in Manila - Post Graduate Course in Urology, Manila, Philippines, 9/3/2018

Maneuvering Through a Rising PSA on a Negative Prostate Biopsy, Speaker, St. Luke's Medical Center in Manila - Post Graduate Course in Urology, Manila, Philippines, 9/3/2018

Metastasis Directed Therapy for Oligometastatic Prostate Cancer, Speaker, St. Luke's Medical Center in Manila - Post Graduate Course in Urology, Manila, Philippines, 9/3/2018

The Paradigm of Oligometastatic Prostate Cancer, Speaker, St. Luke's Medical Center in Manila - Post Graduate Course in Urology, Manila, Philippines, 9/3/2018

Cystectomy and Urinary Robotic Derivation: Myth or Reality, Speaker, 8th Update in Oncological Urology Congress, Lima, Peru, 9/13/2018

Prostate Cancer Poster Session, Moderator, 97th Annual Meeting of the South Central Section of the AUA, Nashville, TN, 9/27/2018

Chapin BF. Gender Equality In Urologic Training, 17th International Prostate Forum, Eastern Section of Japanese Urological Association (EJUA), Grand Nikko Tokyo Daiba, Japan, 10/12/2018

Chapin BF. Layering Systemic Therapy in MO + MI Prostate Cancer, 17th International Prostate Forum, Eastern Section of Japanese Urological Association (EJUA), Grand Nikko Tokyo Daiba, Japan, 10/13/2018

Chapin BF. Local Therapy in Metastatic PCA, 17th International Prostate Forum, Eastern Section of Japanese Urological Association (EJUA), Grand Nikko Tokyo Daiba, Japan, 10/13/2018

Chapin BF. PET in Recurrent PCA, 17th International Prostate Forum, Eastern Section of Japanese Urological Association (EJUA), Grand Nikko Tokyo Daiba, Japan, 10/13/2018

Managing the Challenging Prostate: Advances in RARP Techniques, The British Association of Urological Surgeons - Section of Oncology, York, London, United Kingdom, 12/6/2018

The Evidence for Surgery in High Risk Prostate Cancer, The British Association of Urological Surgeons - Section of Oncology, York, London, United Kingdom, 12/6/2018

Local Therapy in Metastatic Prostate Cancer, 6th Belgium Multidisciplinary Meeting on Urological Cancers, BMUC, Dolce La Hulpe, Brussels, Belgium, 3/30/2019

Chapin BF. Gender Equality in Surgery, Speaker, American Urologic Association Annual Meeting, Chicago, IL, 5/2/2019

Chapin BF. PD15: Prostate Cancer: Advanced (including Drug Therapy) I, Podium Session Moderator, American Urologic Association Annual Meeting, Chicago, IL, 5/3/2019

Chapin BF. Role of Surgery in mHSPC, Speaker, American Urologic Association Annual Meeting, Chicago, IL, 5/4/2019

Chapin BF. Three Papers in the Past Year that Influenced my Practice, Speaker, American Urologic Association Annual Meeting, Chicago, IL, 5/4/2019

Chapin BF. 18th International Prostate Forum, Moderator; Session III: Imaging Update and Imaging Case Discussions, American Urologic Association Annual Meeting, Chicago, IL, 5/5/2019

Chapin BF. Theme 2: Prostate Cancer, Moderator, American Urologic Association Annual Meeting, Chicago, IL, 5/5/2019

Chapin BF. Expert Panel: Challenges & Decision Making in early Prostate Cancer (pivoT & ProtecT), Moderator; Prostate Cancer Foundation (A Unit of The Bengal Urological Trust), CAP Summit 2019, Kolkata, India, 5/24/2019

Chapin BF. Neo Adjuvant Therapy in Localized CaP, Moderator; Prostate Cancer Foundation (A Unit of The Bengal Urological Trust), CAP Summit 2019, Kolkata, India, 5/24/2019

Chapin BF. RARP vs RRT + ADT, Moderator; Prostate Cancer Foundation (A Unit of The Bengal Urological Trust), CAP Summit 2019, Kolkata, India, 5/24/2019

Chapin BF. Panel Discussion: On Locally Adv CaP, Moderator; Prostate Cancer Foundation (A Unit of The Bengal Urological Trust), CAP Summit 2019, Kolkata, India, 5/25/2019

Chapin BF. Role of Local Radiotherapy in Metastatic CaP, Speaker; Prostate Cancer Foundation (A Unit of The Bengal Urological Trust), CAP Summit 2019, Kolkata, India, 5/25/2019

Chapin BF. Tumour Board, Moderator; Prostate Cancer Foundation (A Unit of The Bengal Urological Trust), CAP Summit 2019, Kolkata, India, 5/25/2019

Chapin BF. Complex biologic heterogeneity of de novo hormone naïve metastatic prostate cancer (HNPc): Comparison of early progressors and prolonged responders to initial systemic treatment, Abstract Presentation, 2019 GU ASCO Annual Meeting, Chicago, IL, 6/1/2019

Prostate Cancer: Diagnosis, Prognosis and Treatment, Panel Discussion, 98th Annual Meeting of the South Central Section of the AUA, Colorado Springs, CO, 9/25/2019

Chapin BF. S1802 Update - Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer., Fall 2019 SWOG Group Meeting - Cancer Research Network, Chicago, IL, 10/4/2019

Chapin BF. Cytoreductive Prostatectomy: Treatment of the Primary Tumour in Hormone Sensitive Metastatic Prostate Cancer, Urology Update 2019, University of Toronto, Toronto, Canada, 10/19/2019

Chapin BF. High Risk and Very High Risk Prostate Cancer: Workup and Optimal Management, Urology Update 2019, University of Toronto, Toronto, Canada, 10/19/2019

Pearls of Wisdom from a Medical Plaintiff Attorney, Witness, 2020 Mayo Clinic Urology Review, Waimea, HI, 2/5/2020

Session IV-New Therapies: Mechanisms, Molecules, & Resistance - Overcoming Resistance to Prostate Specific Membrane Antigen (PSMA) Targeted Molecular Radiotherapy (MRT), Discussion Session - 1st Question Discussant, 13th Annual Prostate Cancer Program Retreat, Fort Lauderdale, FL, 3/2/2020

Oligometastatic PC - An Opportunity for Cure, International Speaker Program, Live Webinar on Emerging Treatment Landscape in Prostate Cancer Management-2020, India, 6/7/2020

Prostate Cancer Debate - PRO - To biopsy or not to biopsy, Faculty, SIU 2020 - Around the World Virtual - SIU Innovator's Symposium, 10/11/2020

Surgical Management of Locally Advanced Prostate Cancer, Speaker, ACUOG 2020 Virtual Meeting, Canada, 10/28/2020

Chapin BF. The Current Role of Surgery in Metastatic Prostate Cancer, Global Academic Programs (GAP) 2020 Conference, UT MD Anderson Cancer Center Network - Global Academic Programs, Melbourne, Australia, 11/2020

Chapin BF. Role of Urologic Surgeon in Recurrent Prostate Cancer, Keynote Speaker, Chicago Urological Society Virtual Meeting, Chicago, 11/4/2020

Oligometastatic Prostate Cancer—Clinical Trial Updates and What to do in Clinical Practice Now, Speaker, Eurasian Urooncological Association - 18th International Prostate Virtual Forum, Istanbul, Turkey, 12/12/2020

Other, Including Scientific Exhibitions

Control of the Primary Tumor in Metastatic Prostate, SWOG Cytoreduction Symposium, Chicago, IL, 9/2016

Surgery on Muscle Invasive Oligometastatic Bladder Cancer, 8th Update in Oncological Urology Congress, Lima, Peru, 9/13/2018

Case for RP or RT of the Primary, 19th Annual Meeting of the Society of Urologic Oncology, Society of Urologic Oncology, Phoenix, AZ, 11/29/2018

Seminar Invitations from Other Institutions

Update on Prostate Screening and Therapy, Las Palmas Medical Center, El Paso, TX, 10/2013

Advances in Prostate Cancer, Phillips 66 2014 Health Professionals Conference, The Woodlands, TX, 4/2014

Management of the Spectrum of Prostate Cancer, Essential Health, Duluth, MN, 11/2014

Management of Lymph Node Positive Prostate Cancer and Neoadjuvant Systemic Therapy in Localized Prostate Cancer, 2018 3rd International Prostate Cancer & Urologic Oncology Symposium, The Mount Sinai Hospital, New York, NY, 12/14/2018

Medical Crossfire®: Localized Therapy for Metastatic HSPC? Surgery Versus RT - Evidence for Surgery, 37th Annual CFS: Innovative Cancer Therapy for Tomorrow, Panelist, New York, NY, 11/6/2019

Management of Lymph Node-Positive Prostate Cancer and Neoadjuvant Systemic Therapy in Localized Prostate Cancer, 2019 4th International Prostate Cancer and Urologic Oncology Symposium, Mount Sinai, Urology, New York, NY, 11/7/2019

Prostate Cancer Foundation Global Knowledge Exchange on Oligometastatic Prostate Cancer, Panelist, PCF Global Webinar, 7/6/2020

21st Future Directions in Urology Symposium (FDUS 21) Think Tank, Grand Rounds in Urology and Editor-in-Chief, E. David Crawford, MD, FDUS 21 - Virtual Meeting, 8/10/2020

Extraprostatic extension - Surgical perspective, Society of Abdominal Radiology (SAR) - Virtual Meeting, SAR Prostate Cancer DFP Multidisciplinary Symposium, 8/10/2020

Lectureships and Visiting Professorships

Treatment of the Primary Tumor in Node Positive and Metastatic Prostate Cancer, Urology Grand Rounds, University of Texas Medical School at Houston, Urology, Houston, TX, 1/2013

Treatment of the Primary Tumor in Node Positive and Metastatic Prostate Cancer, LSU Department of Urology Genitourinary Oncology Grand Rounds and Tumor Board, LSU Health New Orleans, Urology, New Orleans, LA, 5/2013

Critical Oncologic Aspects of Surgery in Bladder Cancer, Grand Rounds, University of Texas Medical School at Houston, Urology, Houston, TX, 8/2013

Treatment of the Primary Tumor in Node Positive and Metastatic Prostate Cancer, Massachusetts General Hospital, Urology, Boston, MA, 7/2014

Prostate Cancer, Grand Rounds Conference, University of Texas Medical School at Houston, Urology, Houston, TX, 9/2014

Control of the Primary Tumor in Metastatic Prostate Cancer, Grand Rounds, Baylor College of Medicine, Urology, Houston, TX, 9/2015

Local Treatment in Node Positive and Metastatic Prostate Cancer, Grand Rounds Conference, UT Health Science Center at Houston Medical School, Houston, TX, 10/2015

Treatment of Localized Prostate Cancer, Grand Round, Baylor College of Medicine, Urology, Houston, TX, 11/2015

Control of the Primary Tumor in Node positive and Metastatic Prostate Cancer, Johns Hopkins Hospital, Brady Urological Institute, Baltimore, MD, 2/2016

Definitive Treatment of Primary Tumor in Metastatic Prostate Cancer, University of Texas MD Anderson Cancer Center, Division of Surgery, Houston, TX, 8/2016

Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer, Earl W. Clawater Visiting Professor Lectureship, University of Texas Medical Branch, Urology, Galveston, TX, 8/2016

Treatment of the Prostate in M1 Prostate Adenocarcinoma, Gilbert Tomsy Memorial Lecture, Ochsner Health System, New Orleans, LA, 1/2017

Local Therapy in Metastatic Prostate Cancer, McGovern Lecturership Series, Massachusetts General Hospital, MGH Urology Group, Boston, MA, 2/1/2018

Local Therapy in Metastatic Prostate Cancer, Urology Grand Rounds, NYU Winthrop Hospital, Urology, Mineola, NY, 2/6/2018

Urology: Changing Paradigm of Therapy and Changing Technologies, The Millie A. Berg Visiting Professorship in Honor of Steven P. Petrou, M.D., Mayo Clinic in Florida, Urology, Veda Beach, FL, 10/21/2018

Gender Equality in Surgery and Surgical Training, Grand Rounds, Baylor College of Medicine, Houston, TX, 4/29/2020

Other Presentations at State and Local Conferences

Robotics in Urologic Oncology, Health Adventures, UT MD Anderson Cancer Center, Volunteer Services, Houston, TX, 11/2011

Case Discussions: Reducing the Harms of Treatment, Prostate Health Conference 2012, UT MD Anderson Cancer Center, Urology, Houston, TX, 9/2012

Case Presentations in Prostate Cancer, 7th Urologic Oncology: Advances in Clinical Practice, UT MD Anderson Cancer Center, Urology, Houston, TX, 11/2012

High Risk / Locally Advanced Prostate Cancer - Treatment Options, 7th Urologic Oncology: Advances in Clinical Practice, UT MD Anderson Cancer Center, Urology, Houston, TX, 11/2012

Low Grade / Volume Prostate Cancer, 7th Urologic Oncology: Advances in Clinical Practice, UT MD Anderson Cancer Center, Urology, Houston, TX, 11/2012

Lymph Node Positive Prostate Cancer, 7th Urologic Oncology: Advances in Clinical Practice, UT MD Anderson Cancer Center, Urology, Houston, TX, 11/2012

Recurrent / Metastatic Disease, 7th Urologic Oncology: Advances in Clinical Practice, UT MD Anderson Cancer Center, Urology, Houston, TX, 11/2012

Robotics in Urologic Oncology, Health Adventures, UT MD Anderson Cancer Center, Volunteer Services, Houston, TX, 11/2012

Robotic Assisted Intracorporeal Ileal Conduit Urinary Diversion after Radical Cystoprostatectomy, MINTOS Meet and Greet, UT MD Anderson Cancer Center, MINTOS, Houston, TX, 2/2013

Case Presentations and Discussion in Localized and Locally Advanced Renal Cell Carcinoma, Kidney Cancer Association National Patient Conference, UT MD Anderson Cancer Center, Houston, TX, 4/2013

Global Roundtable Discussion: Understanding and Curing Prostate Cancer: Important Issues, Patient Knowledge, and Support for Prostate Cancer Research, Union for International Cancer Control (UICC), UT MD Anderson Cancer Center, Houston, TX, 4/2013

Critical Oncologic Aspects of Surgery for Bladder Cancer, Bringing the Future of Oncology to Practice Now, MDACC Physicians Network, UT MD Anderson Cancer Center, Orlando, FL, 7/2013

Multimodality Management of Advanced Kidney Cancer, Bringing the Future of Oncology to Practice Now, MDACC Physicians Network, UT MD Anderson Cancer Center, Orlando, FL, 7/2013

Breakthroughs in Imaging Tests to Better Diagnose Cancer, Prostate Health Conference 2013, UT MD Anderson Cancer Center, Houston, TX, 9/2013

Case Presentation in Renal Cancer, 8th Urologic Oncology: Advances in Clinical Practice, UT MD Anderson Cancer Center, Houston, TX, 11/2013

How and When to Extend the Pelvic Lymph Node Dissection, 8th Urologic Oncology: Advances in Clinical Practice, UT MD Anderson Cancer Center, Houston, TX, 11/2013

Management of the Primary Tumor in Advanced Prostate Cancer, 12th Oncology Update: Advances and Controversies, UT MD Anderson Cancer Center, Steamboat Springs, CO, 1/2014

Is there a Role for Surgery in the Setting of Metastatic Kidney Cancer: Cytoreductive Nephrectomy and Metastasectomy, Kidney Cancer Association National Patient Conference, UT MD Anderson Cancer Center, Houston, TX, 4/2014

Control of the Primary Tumor in Node Positive and Metastatic Prostate Cancer, Current Advances in Urology, UT Medical School at Houston, MD Anderson Cancer Center, Memorial Hermann Hospital, Houston, TX, 5/2014

Update: Testicular Cancer, TUS Annual Meeting 2014, Texas Urological Society (TUS), Houston, TX, 6/2014

Prostate Cancer: The Old, The New, and the Future, Perspectives in Clinical Care, Perspectives in Clinical Care, UT MD Anderson Cancer Center, Cancer Prevention, Houston, TX, 1/2015

Neoadjuvant Therapy for Locally Advanced Prostate Cancer: Current Status in 2016, 14th Oncology Update: Advances and Controversies, MDACC Physicians Network, UT MD Anderson Cancer Center, Steamboat Springs, CO, 1/2016

Robotic Assisted Surgery in Prostate Cancer: The Good, The Bad, and The Ugly, Tex US Too, Inc, Houston, TX, 1/2016

Neoadjuvant Therapy for Prostate Cancer, Arkansas Urologic Society, Little Rock, AR, 8/2016

Prostate Cancer, FCNA-MH Annual Cancer Symposium, Filipino Center Network of America-Metro Houston, Houston, TX, 8/2016

The Role of Prostatectomy in Advanced Prostate Cancer, Prostate Cancer Educational Program, University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, TX, 8/2016

Neoadjuvant Therapy for Prostate Cancer, Arkansas Urologic Society Annual Meeting, Arkansas Urologic Society, Little Rock, AR, 9/2016

Surgery in Metastatic Prostate Cancer, Southern Society of Urologic Surgeons, Santa Fe, NM, 10/2016

Management of Node Positive Prostate Cancer, 15th Oncology Update: Advances and Controversies, UT MD Anderson Cancer Center, Steamboat Springs, CO, 1/2017

Surgery for High Risk Prostate Adenocarcinoma, Ochsner Health System, New Orleans, LA, 1/2017

Chapin, BF. Robotic Surgery for High Risk Prostate Cancer, Prostate Cancer Education and Support, Tex Us TOO, Inc., Houston, TX, 10/2017

Case Discussions, 12th Annual Physicians Network Symposium: Novel and Exciting Advances in Cancer Therapeutics and Future Prospects - GU Tumors - Novel Therapeutic Concepts in GU Cancers, MDACC Physicians Network Symposium, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/22/2017

Control of the Primary Tumor in Metastatic Prostate Cancer, 12th Annual Physicians Network Symposium: Novel and Exciting Advances in Cancer Therapeutics and Future Prospects - GU Tumors - Novel Therapeutic Concepts in GU Cancers, MDACC Physicians Network Symposium, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/22/2017

Control of the Primary Tumor Improves Outcomes in Patients With Metastatic Prostate Cancer?, 16th Oncology Update: Advances and Controversies, MDACC Physicians Network, UT MD Anderson Cancer Center, Steamboat Springs, CO, 1/2018

Debate: Prostate Cancer Screening - Pro: MRI First. Moderator: Session IV: Prostate Cancer, 13th Update on the Management of Genitourinary Malignancies, UT MD Anderson Cancer Center, Houston, TX, 11/2018

Neoadjuvant System Therapy for Advanced PCa, 13th Update on the Management of Genitourinary Malignancies, UT MD Anderson Cancer Center, Houston, TX, 11/2018

Chapin BF. Does Control of the Primary Tumor Improve Outcomes in Metastatic GU Cancers? - Prostate Cancer, 17th Oncology Update: Advances and Controversies, MDACC Physicians Network, UT MD Anderson Cancer Center, Breckenridge, CO, 1/20/2019

Urologists in Clinical Trials, Friday Special Lecture Series - SUO, UT MD Anderson Cancer Center, Urology, Virtual Series, 4/10/2020

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Urological Association (AUA)
Candidate Member, 2006-present

Endourological Society
Member, 2006-present

Sexual Medicine Society of North America (SMSNA)
Candidate Member, 2009-present

American Society of Clinical Oncology (ASCO)
Associate Member, 2010-present

European Association of Urology (EAU)
Junior International Member, 2010-present

Society of Urologic Oncology (SUO)
Candidate Member, 2011-present

South Central Section of the American Urological Association (SCSAUA)
Candidate Member, 2012-present

Southwest Oncology Group (SWOG)
Member, 4/2013-present

SIU Multimedia Learning Committee Prostate/Metastatic sub-committee
Expert Consultant, 9/2015-present

Congressionally Directed Medical Research Programs
Grant Reviewer, 2016

Society of Urologic Oncology
Y.U.O. Board Member, 12/2016-present

Netherlands Organization for Scientific Research
External Grant Reviewer, 2017

Societe Internationale D'Urologie (SIU)
Member, Prostate Committee, 2017-present

SIU Academy Sub-Committee - Prostate Cancer
Member, 3/2018-present

Society of Urologic Oncology (SUO)
Education Committee Member, 12/2019-12/2020

Society of Urologic Oncology (SUO)
Board Member, 12/2019-present

Local/State

Harris County Medical Society

Member, 2011-present
Graduate Medical Education Committee (GMEC)
Associate Member, 2013-present

UNIQUE ACTIVITIES

1. Radio Interview - Sirius Radio - Doctor Radio - Prostate Cancer - April 26th, 2017
2. Radio Interview - Sirius Radio - Doctor Radio - Clinical Trials in Prostate Cancer - April 25, 2018
3. Radio Interview - Texas Public Radio - Prostate Cancer - September 30th, 2019

DATE OF LAST CV UPDATE

10/21/2020